Synapse - Rohit Thummalapalli

Results (22)

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

Journal Article

Middha, P.; Thummalapalli, R.; Quandt, Z.; Balaratnam, K.; Cardenas, E.; Falcon, C. J.; Princess Margaret Lung Group; Gubens, M. A.; Huntsman, S.; Khan, K.; more...
Journal for ImmunoTherapy of Cancer (2025)

Fulltext@MSK | Save

Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer

Journal Article

Zucker, M.; Perry, M. A.; Gould, S. I.; Elkrief, A.; Safonov, A.; Thummalapalli, R.; Mehine, M.; Chakravarty, D.; Brannon, A. R.; Ladanyi, M.; more...
Cell (2025)

Fulltext@MSK | Save

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Journal Article

Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Ricciuti, B.; Digumarthy, S.; Alessi, J. V.; Gogia, P.; Pecci, F.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies

Meeting Abstract

Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC

Journal Article

Nassar, A. H.; Jayakrishnan, R.; Feng, J.; Shepherd, F.; Adib, E.; Cheung, J. M.; Lin, J. J.; Liu, Y.; Lin, S. H.; Parikh, K.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Divergent clinical and immunologic outcomes based on STK11 Co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade

Journal Article

Rosner, S.; Connor, S.; Sanber, K.; Zahurak, M.; Zhang, T.; Gurumurthy, I.; Zeng, Z.; Presson, B.; Singh, D.; Rayes, R.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Clinical outcomes and immunotherapy retreatment in patients with metastatic NSCLC who complete at least two years of immune checkpoint blockade

Meeting Abstract

Ricciuti, B.; Hong, L.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Awosika, N.; Mollica, L.; Citarella, F.; Gandhi, M.; Elkrief, A.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Meeting Abstract

Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma

Meeting Abstract

Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC

Meeting Abstract

Thummalapalli, R.; Muldoon, D.; Febres-Aldana, C. A.; Falcon, C. J.; Pupo, A.; Bandlamudi, C.; Berger, M. F.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save